Concord Biotech Balance Sheet Health
Financial Health criteria checks 6/6
Concord Biotech has a total shareholder equity of ₹15.9B and total debt of ₹0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ₹17.6B and ₹1.7B respectively. Concord Biotech's EBIT is ₹4.1B making its interest coverage ratio -236.6. It has cash and short-term investments of ₹2.8B.
Key information
0%
Debt to equity ratio
₹0
Debt
| Interest coverage ratio | -236.6x |
| Cash | ₹2.84b |
| Equity | ₹15.90b |
| Total liabilities | ₹1.74b |
| Total assets | ₹17.64b |
Recent financial health updates
Recent updates
Concord Biotech Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Nov 14
Do Concord Biotech's (NSE:CONCORDBIO) Earnings Warrant Your Attention?
Sep 15Concord Biotech Limited (NSE:CONCORDBIO) Not Lagging Market On Growth Or Pricing
Jul 23Is Concord Biotech (NSE:CONCORDBIO) Using Too Much Debt?
Feb 14Financial Position Analysis
Short Term Liabilities: CONCORDBIO's short term assets (₹9.3B) exceed its short term liabilities (₹1.4B).
Long Term Liabilities: CONCORDBIO's short term assets (₹9.3B) exceed its long term liabilities (₹322.5M).
Debt to Equity History and Analysis
Debt Level: CONCORDBIO is debt free.
Reducing Debt: CONCORDBIO had no debt 5 years ago.
Debt Coverage: CONCORDBIO has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CONCORDBIO has no debt, therefore coverage of interest payments is not a concern.